Alkermes plc ALKS

NAS: ALKS | ISIN: IE00B56GVS15   17/09/2026
46,71 USD (+1,39%)
(+1,39%)   17/09/2026

19 november 2025 · Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc · Persbericht

14 november 2025 · Alkermes Response to Avadel Announcement · Persbericht

12 november 2025 · Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2 · Persbericht

6 november 2025 · Alkermes to Participate in Two Upcoming Investor Conferences · Persbericht

5 november 2025 · FORM 8.1(a) & (b) (Opening Position Disclosure) · Persbericht

28 oktober 2025 · Alkermes plc Reports Third Quarter 2025 Financial Results · Persbericht

22 oktober 2025 · Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc · Persbericht

20 oktober 2025 · Alkermes to Report Third Quarter Financial Results on October 28, 2025 · Persbericht

12 september 2025 · Alkermes Appoints Joshua Reed as Chief Financial Officer · Persbericht

11 september 2025 · Alkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards® Program · Persbericht

8 september 2025 · Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025 · Persbericht

25 augustus 2025 · Alkermes to Present Detailed Positive Results From Vibrance-1 Phase 2 Study Evaluating Alixorexton in Patients With Narcolepsy Type 1 at World Sleep 2025 · Persbericht

29 juli 2025 · Alkermes plc Reports Second Quarter 2025 Financial Results · Persbericht

21 juli 2025 · Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1 · Persbericht

15 juli 2025 · Alkermes to Report Second Quarter Financial Results on July 29, 2025 · Persbericht

2 juni 2025 · Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference · Persbericht

2 juni 2025 · Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences · Persbericht

29 mei 2025 · Alkermes to Present New Research Related to ALKS 2680 at SLEEP 2025 · Persbericht

1 mei 2025 · Alkermes plc Reports First Quarter 2025 Financial Results · Persbericht

30 april 2025 · New Survey Provides Insights into Diagnosis and Treatment Journey for People Living With Alcohol Use Disorder (AUD) · Persbericht

Mijn selecties